MX2018003649A - Metodos e intermedios para la preparacion de derivados de acido biliar. - Google Patents

Metodos e intermedios para la preparacion de derivados de acido biliar.

Info

Publication number
MX2018003649A
MX2018003649A MX2018003649A MX2018003649A MX2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A
Authority
MX
Mexico
Prior art keywords
methods
acid derivatives
bile acid
intermediates
preparation
Prior art date
Application number
MX2018003649A
Other languages
English (en)
Inventor
Schaab Kevin
E Whitley Paul
Chavez Flavio
R Iorga Kayla
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018003649A publication Critical patent/MX2018003649A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invenci6n se refiere a métodos e intermedios novedosos útiles en la preparación de un compuesto o una sal farmacéuticamente aceptable del mismo. Un objetivo de la presente invención es proporcionar métodos para preparar derivados de ácidos biliares e intermedios novedosos. Un use de los métodos e intermedios descritos se refiere a la síntesis de derivados de ácidos biliares que activan tanto FXR como TGR5.
MX2018003649A 2015-09-24 2016-09-23 Metodos e intermedios para la preparacion de derivados de acido biliar. MX2018003649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222943P 2015-09-24 2015-09-24
PCT/US2016/053483 WO2017053826A1 (en) 2015-09-24 2016-09-23 Methods and intermediates for the preparation bile acid derivatives

Publications (1)

Publication Number Publication Date
MX2018003649A true MX2018003649A (es) 2018-05-11

Family

ID=58387485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003649A MX2018003649A (es) 2015-09-24 2016-09-23 Metodos e intermedios para la preparacion de derivados de acido biliar.

Country Status (13)

Country Link
US (1) US11072631B2 (es)
EP (1) EP3353189A4 (es)
JP (1) JP2018528230A (es)
KR (1) KR20180052756A (es)
CN (1) CN108350020A (es)
AR (1) AR106141A1 (es)
AU (1) AU2016325619A1 (es)
CA (1) CA2999302A1 (es)
HK (1) HK1254057A1 (es)
IL (1) IL258113A (es)
MX (1) MX2018003649A (es)
TW (1) TW201718622A (es)
WO (1) WO2017053826A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533923A (ja) 2014-11-06 2017-11-16 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SG10201910670RA (en) 2015-03-31 2020-01-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CA3038534A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc. Crystalline forms of a bile acid derivative
CN110121347A (zh) 2016-11-29 2019-08-13 英安塔制药有限公司 制备磺酰脲胆汁酸衍生物的方法
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN110869381B (zh) * 2017-07-26 2021-11-19 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂的制备方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
MX2011005295A (es) * 2008-11-19 2011-06-24 Intercept Pharmaceuticals Inc Moduladores de tgr5 y metodo de uso de los mismos.
SG11201408501UA (en) 2012-06-19 2015-01-29 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
DK2912013T3 (en) * 2012-10-26 2018-01-15 Intercept Pharmaceuticals Inc Process for the preparation of bile acid derivatives
EP2925328A1 (en) 2012-11-28 2015-10-07 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
DK3626725T3 (da) * 2014-05-29 2023-02-27 Bar Pharmaceuticals S R L Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme
JP7306791B2 (ja) 2015-02-06 2023-07-11 インターセプト ファーマシューティカルズ， インコーポレイテッド 併用療法のための医薬組成物
EP3331896A4 (en) * 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESSES FOR PREPARING BILIARY ACIDS AND THEIR DERIVATIVES
JP6824966B2 (ja) 2015-09-21 2021-02-03 インターセプト ファーマシューティカルズ， インコーポレイテッド 肝臓の再生を促進する方法

Also Published As

Publication number Publication date
US11072631B2 (en) 2021-07-27
JP2018528230A (ja) 2018-09-27
EP3353189A4 (en) 2019-06-19
WO2017053826A1 (en) 2017-03-30
TW201718622A (zh) 2017-06-01
AR106141A1 (es) 2017-12-13
HK1254057A1 (zh) 2019-07-12
IL258113A (en) 2018-05-31
AU2016325619A1 (en) 2018-04-12
KR20180052756A (ko) 2018-05-18
EP3353189A1 (en) 2018-08-01
US20200239515A1 (en) 2020-07-30
CN108350020A (zh) 2018-07-31
CA2999302A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
IL304455A (en) Methods and intermediates for the preparation of bile acid derivatives
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
IN2013MU02828A (es)
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
PH12017500595A1 (en) Aldosterone synthase inhibitors
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
IN2014DN08443A (es)
IN2013MU04056A (es)
PH12017500492A1 (en) Crystalline bace inhibitors
IN2015CH02092A (es)
IN2013MU02813A (es)
IN2014CH01391A (es)
IN2013MU02612A (es)
IN2014MU00070A (es)
IN2014MU00071A (es)